Calreticulin is a Ca (2+)-buffering chaperone of the endoplasmic reticulum. The protein is highly expressed in embryonic heart but downregulated in postnatal heart, indicating that expression of calreticulin in the heart is highly regulated. In this study we identify GATA6 and Evi-1 transcription factors as new regulators of the calreticulin gene. In neonatal rat ventricular cardiomyocytes and mouse fibroblasts the calreticulin gene is activated by GATA6 but repressed by Evi-1. Furthermore, transactivation of the calreticulin gene by GATA6 is suppressed by Evi-1, suggesting an antagonistic role between both GATA6 and Evi-1. Using EMSA, ChIP analysis, and site-specific mutagenesis, we showed that GATA6 and Evi-1 bind to site 1 on the calreticulin promoter. GATA6 and Evi-1 are highly expressed early during cardiogenesis of ES cells, suggesting that they may regulate expression of the calreticulin gene during cardiac development.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/bi702524v | DOI Listing |
Cureus
December 2024
Internal Medicine, National Hospital of Sri Lanka, Colombo, LKA.
Hereditary hemochromatosis occurs due to genetic mutations, namely, cysteine-to-tyrosine substitution at amino acid 282 (C282Y) and histidine-to-aspartic acid substitution at 63 (H63D) mutations. The role of H63D mutation in hemochromatosis is less clear, and its penetrance is low even in homozygotes. Therefore, iron overload in H63D heterozygotes is extremely rare and scarcely reported.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Department of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.
Calreticulin (CRT) is a 46 kDa highly conserved protein initially identified as calregulin, a prominent Ca-binding protein of the endoplasmic reticulum (ER). Subsequent studies have established that CRT functions in the ER's protein folding response and Ca homeostatic mechanisms. An ER retention signal on the carboxyl terminus of CRT suggested that CRT was restricted to the ER.
View Article and Find Full Text PDFClin Cancer Res
January 2025
University of Leeds, Leeds, United Kingdom.
Background: Effective treatment for patients with metastatic cancer is limited, particularly for colorectal cancer patients with metastatic liver lesions (mCRC), where accessibility to numerous tumours is essential for favourable clinical outcomes. Oncolytic viruses (OVs) selectively replicate in cancer cells; however, direct targeting of inaccessible lesions is limited when using conventional intravenous or intratumoural administration routes.
Methods: We conducted a multi-centre, dose-escalation, phase I study of vaccinia virus, TG6002, via intrahepatic artery (IHA) delivery in combination with the oral pro-drug 5-fluorocytosine to fifteen mCRC patients.
bioRxiv
December 2024
Pediatrics and Rare Diseases Group, Sanford Research, Sioux Falls, SD, United States.
Beta-propeller Protein Associated Neurodegeneration (BPAN) is a devastating neurodevelopmental and neurodegenerative disease linked to variants in . Currently, there is no cure or disease altering treatment for this disease. This is, in part, due to a lack of insight into early phenotypes of BPAN progression and 's role in establishing and maintaining neurological function.
View Article and Find Full Text PDFJ Radiat Res
January 2025
Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Recently, ultra-high dose rate (> 40 Gy/s, uHDR; FLASH) radiation therapy (RT) has attracted interest, because the FLASH effect that is, while a cell-killing effect on cancer cells remains, the damage to normal tissue could be spared has been reported. This study aimed to compare the immune-related protein expression on cancer cells after γ-ray, conventionally used dose rate (Conv) carbon ion (C-ion), and uHDR C-ion. B16F10 murine melanoma and Pan02 murine pancreas cancer were irradiated with γ-ray at Osaka University and with C-ion at Osaka HIMAK.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!